Out-licensing
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
A series of SynLeptin peptides, particularly, SynLeptin-2 shows remarkable anti-obesity activities which were verified in animal experiments using mice and rabbits. More
Transgenic mice for screening compounds with therapeutic potential against pain, hyper-thyroidism or obesity. These transgenic mice over-express DREAM, a transcriptional repressor More
Proprietary supercritical fluid (SCF) technology to improve bioavailability, enhance stability and optimise drug delivery for small and large molecules in a range of dosage forms More
Enhancing the dissolution performance of small and large molecules in a range of dosage forms More
Increasing the stability and improving the reconstitution of biomolecules using supercritical fluid (SCF) processing More
Crystal and particle engineering to form particles with strong aerodynamic performance and exceptional size uniformity for optimised pulmonary/nasal delivery More
Related Reports
Market Research Reports provided by reports.innovaro.com
Dec 2010 - 4 pages - $500
Apr 2007 - 21 pages - $5,695
Feb 2011 - 102 pages - $2,615
Aug 2011 - 60 pages - $5,700
May 2011 - 40 pages - $3,800
Jul 2008 - 148 pages - $3,835
Jul 2009 - $15,200
Nov 2010 - 414 pages - $1,495
Dec 2010 - 38 pages - $2,000
Jul 2011 - 72 pages - $11,400
Your selection
Browse By
- Industry sector
- Animal health
- Biotechnology
- Diagnostic
- Drug delivery
- Drug discovery
- Medical device
- Pharmaceutical
- Research tools
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1998-2012 Innovaro Europe Ltd 
All rights reserved. Terms and Conditions | Contact us